Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study (vol 35, pg 141, 2017)

Perez

首页> 外文期刊>Journal of Clinical Oncology >Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study (vol 35, pg 141, 2017)

【24h】

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study (vol 35, pg 141, 2017)

机译：曲妥珠单抗与Pertuzumab与retsuzumab和紫罗兰人为人体表皮生长因子受体2阳性，晚期乳腺癌的紫罗兰毒素：III期玛丽安学习的主要结果（Vol 35，PG 141,2017）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of Clinical Oncology》 |2017年第20期|共1页
作者
Perez;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
专利

1. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study (vol 35, pg 141, 2017) [J] . Perez Journal of Clinical Oncology . 2017,第20期

机译：曲妥珠单抗与Pertuzumab与retsuzumab和紫罗兰人为人体表皮生长因子受体2阳性，晚期乳腺癌的紫罗兰毒素：III期玛丽安学习的主要结果（Vol 35，PG 141,2017）
2. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE [J] . Perez Edith A., Barrios Carlos, Eiermann Wolfgang, Cancer: A Journal of the American Cancer Society . 2019,第22期

机译：Trastuzumab emtansine有或没有Pertuzumab与脂肪株与人表皮生长因子受体2阳性晚期乳腺癌的脂肪株：来自Marianne的最终结果
3. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer [J] . Edith A. Perez, Sanne Lysbet de Haas, Wolfgang Eiermann, BMC Cancer . 2019,第1期

机译：肿瘤生物标志物与Marianne疗效的关系，III研究曲妥珠单抗±Pertuzumab与曲妥珠单抗加紫罗兰在Her2阳性晚期乳腺癌中的研究
4. Identification of Human Epidermal Growth Factor Receptor 2 Antagonist In Silico for Breast Cancer Therapy, Derived from Indonesian Phytochemicals [C] . Tuti Ratnasari, Dono indarto, Raden Ajeng Sri Wulandari, International Conference on Biomedical Engineering . 2018

机译：人类表皮生长因子受体2拮抗剂在二氧化硅中用于印尼治疗的印尼植物化学成分的鉴定。
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study [O] . Edith A. Perez, Carlos Barrios, Wolfgang Eiermann, -1

机译：曲妥珠单抗Emtansine与或不与曲妥珠单抗相比曲妥珠单抗加紫杉烷对人类表皮生长因子受体2阳性晚期乳腺癌的研究：III期MARIANNE研究的主要结果
7. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: Primary results from the phase III MARIANNE study [O] . Perez, Edith A., Barrios, Carlos, Eiermann, Wolfgang, 2017

机译：曲妥珠单抗Emtansine联合或不联合帕妥珠单抗与曲妥珠单抗加紫杉烷治疗人表皮生长因子受体2阳性晚期乳腺癌：MARIANNE III期研究的主要结果

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study (vol 35, pg 141, 2017)

著录项

相似文献

相关主题

期刊订阅